OBJECTIVE: To compare persistence and adherence among patients with chronic obstructive pulmonary disease (COPD) treated with either multiple- or single- long-acting maintenance inhalers. METHODS: Patients with ≥2 COPD medical claims and ≥2 prescriptions for a long-acting inhaler within 1 year were classified as single- or multiple-inhaler users based on their treatment regimen (MarketScan database; 2004-2008) and matched on demographics and statistically significant baseline characteristics. Persistence, analyzed via time to treatment discontinuation, and treatment adherence, measured by proportion of days covered (PDC), were compared between the two groups over a 12-month period. Sensitivity analyses were conducted in patients with poorly and well-controlled disease. RESULTS: A total of 23,494 patients were grouped into 11,747 matched pairs. After adjusting for confounding factors, multiple-inhaler users had a significantly higher discontinuation rate [Hazard ratio = 1.40, p < 0.0001] compared with single-inhaler users. Multiple-inhaler users were less likely to be adherent than single-inhaler users with an average PDC of 0.51 (SD = 0.272) vs. 0.55 (SD = 0.279), respectively (p < 0.0001). These results were consistent for the poorly- and well-controlled disease groups. CONCLUSIONS: Multiple long-acting inhaler users demonstrated lower treatment persistence and adherence rates than single long-acting inhaler users. Limitations of the study are related to the retrospective, observational design and use of claims data.
OBJECTIVE: To compare persistence and adherence among patients with chronic obstructive pulmonary disease (COPD) treated with either multiple- or single- long-acting maintenance inhalers. METHODS:Patients with ≥2 COPD medical claims and ≥2 prescriptions for a long-acting inhaler within 1 year were classified as single- or multiple-inhaler users based on their treatment regimen (MarketScan database; 2004-2008) and matched on demographics and statistically significant baseline characteristics. Persistence, analyzed via time to treatment discontinuation, and treatment adherence, measured by proportion of days covered (PDC), were compared between the two groups over a 12-month period. Sensitivity analyses were conducted in patients with poorly and well-controlled disease. RESULTS: A total of 23,494 patients were grouped into 11,747 matched pairs. After adjusting for confounding factors, multiple-inhaler users had a significantly higher discontinuation rate [Hazard ratio = 1.40, p < 0.0001] compared with single-inhaler users. Multiple-inhaler users were less likely to be adherent than single-inhaler users with an average PDC of 0.51 (SD = 0.272) vs. 0.55 (SD = 0.279), respectively (p < 0.0001). These results were consistent for the poorly- and well-controlled disease groups. CONCLUSIONS: Multiple long-acting inhaler users demonstrated lower treatment persistence and adherence rates than single long-acting inhaler users. Limitations of the study are related to the retrospective, observational design and use of claims data.
Authors: Jennifer S Albrecht; Bilal Khokhar; Ting-Ying Huang; Yu-Jung Wei; Ilene Harris; Patience Moyo; Peter Hur; Susan W Lehmann; Giora Netzer; Linda Simoni-Wastila Journal: Respir Med Date: 2017-06-03 Impact factor: 3.415
Authors: Timothy E Albertson; Michael Schivo; Amir A Zeki; Samuel Louie; Mark E Sutter; Mark Avdalovic; Andrew L Chan Journal: Drugs Aging Date: 2013-07 Impact factor: 3.923
Authors: Melanie Schroeder; Nicole Benjamin; Laura Atienza; Chandroday Biswas; Alan Martin; John D Whalen; José Luis Izquierdo Alonso; Juan Antonio Riesco Miranda; Juan José Soler-Cataluña; Alicia Huerta; Afisi S Ismaila Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-07-10
Authors: Jennifer S Albrecht; Yujin Park; Peter Hur; Ting-Ying Huang; Ilene Harris; Giora Netzer; Susan W Lehmann; Patricia Langenberg; Bilal Khokhar; Yu-Jung Wei; Patience Moyo; Linda Simoni-Wastila Journal: Ann Am Thorac Soc Date: 2016-09
Authors: Arnaud Bourdin; Nicolas Molinari; Gary T Ferguson; Barinder Singh; Mohd Kashif Siddiqui; Ulf Holmgren; Mario Ouwens; Martin Jenkins; Enrico De Nigris Journal: Adv Ther Date: 2021-04-30 Impact factor: 3.845